Hong Kong Stock Movement
Akeso Inc. rose over 10%. Based on recent key news:
<ol>
<li>On March 10, Akeso announced that its globally innovative trispecific antibody new drug AK150 has entered the clinical trial stage, receiving the implied approval for clinical trials from the National Medical Products Administration's Drug Evaluation Center. This news drove the stock price up, peaking at HKD 115.3, with a transaction volume of HKD 940 million. Source: Zhitong Finance, the biopharmaceutical industry is driven by innovation, with significant capital inflow.</li>
</ol>
Stocks with High Transaction Volume in the Industry
Innovent Biologics rose 3.79%. Based on recent news,
<ol>
<li>
On March 6, Innovent Biologics had six products newly included in the national medical insurance catalog, but the subsequent significant price reductions affected revenue growth. Bank of America Securities pointed out that in the fourth quarter of 2025, inventory price adjustments dragged down revenue growth performance for that quarter. China International Capital Corporation also mentioned that if this impact is excluded, Innovent Biologics' actual revenue growth in the fourth quarter would have been more impressive.
</li>
<li>
On March 7, Innovent Biologics is actively adjusting its layout through strategic cooperation and pipeline focus. Facing the dual challenges of slowing growth in core products and intense competition in the GLP-1 sector, Innovent Biologics is optimizing its cash flow structure, shifting more resources towards the commercialization promotion and capacity optimization of already listed products.
</li>
<li>
On March 10, Innovent Biologics' IBI363 showed positive progress in a phase III lung cancer trial supported by Takeda, boosting market confidence. The competition in the innovative drug industry is fierce, and attention should be paid to changes in market share.
</li>
</ol>
3SBio Inc. rose 5.48%. Based on recent key news:
<ol>
<li>
On March 9, 3SBio's stock price rose 5.48%, with a transaction volume reaching HKD 352 million. According to Zhitong Finance, 3SBio has recently made breakthroughs in research and development, particularly in the innovation of anti-cancer drugs, attracting market attention and active buying from investors, driving the stock price up.
</li>
<li>
On March 8, 3SBio announced a strategic cooperation agreement with an internationally renowned pharmaceutical company aimed at jointly developing new drugs. This cooperation is seen by the market as a strong driver for the company's future growth, further enhancing investor confidence and leading to a rise in stock price.
</li>
<li>
On March 7, analysts generally raised their earnings forecasts for 3SBio, expecting significant improvement in its performance over the next few quarters. Analysts' optimistic expectations have strengthened market sentiment towards the stock, driving the stock price up. The pharmaceutical industry has recently performed strongly, with significant capital inflow.
</li>
</ol>
BeiGene rose 2.63%. Based on recent news,
<ol>
<li>
On March 7, BeiGene announced that its drug zanubrutinib in the CLL field has achieved significant market share and plans to further expand into the fixed-duration treatment market. This news boosted investor confidence, driving the stock price up.
</li>
<li>
On March 7, several cornerstone products of BeiGene in the hematologic oncology field are nearing commercialization, particularly the BCL2 inhibitor, which has obtained the first global marketing authorization application approval in China. This progress further enhances market confidence in the company
On March 7th, BeiGene announced that it completed clinical concept validation for 5 new products in 2025 and advanced 17 new molecular entities to the clinical stage. This indicates significant progress in the company's R&amp;D innovation, further driving up the stock price. The biopharmaceutical industry is performing strongly overall, with noticeable capital inflow.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Kelong Botai Bio-B rose by 7.37%. Based on recent news,
<ol>
<li>
On March 9th, Kelong Botai Bio announced that the clinical trial application for the long-acting bispecific antibody SKB575, targeting thymic stromal lymphopoietin and an undisclosed target, developed in collaboration with HeBo Pharmaceuticals, has been approved by the National Medical Products Administration of China for the treatment of atopic dermatitis. This news boosted market confidence and drove up the stock price.
</li>
<li>
On March 9th, Kelong Botai Bio announced that SKB575/HBM7575 is led by the company in design, global development, and commercialization, with HeBo Pharmaceuticals participating in investment and development and sharing profits. This announcement further enhanced investors' confidence in the company's future development.
</li>
<li>
On March 10th, market analysis pointed out that Kelong Botai Bio ranks among the top securities with the highest short-term speculative value, attracting a large inflow of short-term funds, driving up the stock price. The pharmaceutical industry has performed strongly recently, boosting investor confidence
</li>
</ol>

09926

AKESO rose 10.90%; Innovent Biologics rose 3.79%, with a transaction volume of HKD 404 million; 3SBio rose 5.48%, with a transaction volume of HKD 352 million; BeiGene rose 2.63%, with a transaction volume of HKD 309 million; Kelun-Bio rose 7.37%, with a market value of HKD 95.1 billion

Hong Kong Stock Movement: AKESO's tri-specific antibody approved for clinical trials, stock price surges over 10%, attracting market attention